Tolerability of ziprasidone: an expanding perspective

Area of Science:

• Psychiatry and Pharmacology
• Clinical Therapeutics

Background:

• Atypical antipsychotics improve schizophrenia management but have metabolic side effects like weight gain and dyslipidemia.
• Ziprasidone presents a potential alternative with a different safety profile.

Purpose of the Study:

• To review the safety and tolerability of ziprasidone, including intramuscular and oral formulations.
• To evaluate ziprasidone's metabolic profile compared to placebo and active comparators.

Main Methods:

• Review of pharmacokinetic and clinical trials.
• Comparison of ziprasidone with placebo and other antipsychotic agents.

Main Results:

• Ziprasidone demonstrates a favorable metabolic profile with negligible weight gain and minimal effects on glucose and lipid levels.
• Low liability for movement disorders and good tolerability in clinical trials.
• Limited effect on the corrected QT interval (QTc) without demonstrated increased clinical risk.

Conclusions:

• Ziprasidone offers a favorable safety and tolerability profile for schizophrenia management.
• Its metabolic neutrality and low risk of QTc prolongation make it a valuable treatment option.